What we do
The Alzheimer’s Research UK UCL Drug Discovery Institute is situated in the historic Cruciform building.
We will couple sophisticated drug discovery capabilities with deep disease-specific expertise – from basic science through to clinical understanding – throughout the University and beyond, to identify and validate new therapeutic targets. We will work closely with industrial partners and other organisations to ensure successful candidates continue through the drug discovery pipeline towards patients.
We look to forge collaborations with academic and industrial partners as we seek out new targets for neurodegenerative disease. Find out more about how we can act as a conduit between your research and novel therapeutics.
The UCL Drug Discovery Institute is part of a wider Drug Discovery Alliance, funded by Alzheimer’s Research UK and launched in 2015. The UCL Drug Discovery Institute will work alongside Institutes at the University of Oxford and University of Cambridge to create one of the largest coordinated efforts to streamline academic drug discovery into neurodegenerative diseases. Our aim is to meet the unmet clinical need of 850,000 people in the UK and many millions across the world, living with dementia.
If you would like more information about the Alliance, its operation or governance, please contact the Research team at Alzheimer’s Research UK.